NewsRx

Search our medical news database

Sexual & Reproductive Health

Study shows patient preference for Gonal-F RFF PEN to treat infertility

Published in Drug Week, November 17th, 2006

Serono (SRA) announced the results of a Phase IIIb, prospective, open-label study in which patients reported they preferred the Gonal-f(r) RFF Pen (follitropin alfa injection) to their previous fertility treatment with conventional vials/ampules and syringes.

The study was published by the peer-reviewed journal Current Medical Research and Opinion.

"Patient satisfaction is a critical component to infertility treatment success," said Stephen G. Somkuti, MD, PhD, the lead author and coordinating investigator from Abington Reproductive Medicine, Abington, Penn. "By providing products that patients prefer, fertility centers may minimize treatment...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook